AUTHORS
Louise Ainley, MD, Amatta Mirandari, PhD2, Elise Rees, PhD3, Emma Lyon4, Rethina Shritharan5, Daniel Hughes6, Kane Foster, PhD7, Annabel Laidler8, Bethan Hudson-Lund, PhD9, Janice Sim10, Daria Galas Filipowicz11, Dylan Jankovic12, Filippo Viviani13, Grant Vallance14, Ceri Bygrave, MBBCh15, Karthik Ramasamy, MD PhD16, Laura McCoy17, Reuben Tooze, PhD, MBBS, FRCPath18, Eileen Boyle, MD PhD19, Lydia Sarah Hui Lee, MBBS, MRCP, MRCPath(Haem), PhD20, Dinis Calado21, Kwee Yong, MD, PhD22
AFFILIATIONS
1 University College London, London, United Kingdom
2 University College London, London, United Kingdom
3 University College London, London, United Kingdom
4 University College London, London, United Kingdom
5 University College London, London, United Kingdom
6 University College London, London, United Kingdom
7 Dana Farber Cancer Institute, Boston, United States
8 University College London, London, United Kingdom
9 University College London, London, United Kingdom
10 University College London, London, United Kingdom
11 University College London, London, United Kingdom
12 University College London, London, United Kingdom
13 University College London, London, United Kingdom
14 Oxford University NHS Foundation Trust, Oxford, United Kingdom
15 Cardiff and Vale UHB, Cardiff, United Kingdom
16 Oxford University NHS Foundation Trust, Oxford, United Kingdom
17 University College London, London, United Kingdom
18 University Of Leeds, Leeds, United Kingdom
19 University College London, London, United Kingdom
20 University College London, London, United Kingdom
21 The Francis Crick Institute, London, United Kingdom
22 University College London, London, United Kingdom
ABSTRACT
Background:
Multiple myeloma (MM) is preceded by precursor conditions, monoclonal gammopathy of unknown significance (MGUS) and smouldering myeloma (SMM). Progression risk is variable and not fully explained by tumour factors. While changes in T, NK and myeloid cells have been described, the B-cell compartment remains poorly understood despite the frequent infections and impaired vaccine responses seen in patients. B cells can also exert immunoregulatory effects through IL-10. We therefore characterised B-cell subsets across precursor disease and newly diagnosed MM (NDMM), including their capacity to produce IL-10.
Methods:
Bone marrow (BM) and peripheral blood (PB) were obtained from patients in clinical trials for precursor disease (COSMOS, NCT05047107) and NDMM (RADAR). Age-matched healthy-donor (HD) PB was obtained through the UCL/UCLH Biobank. Fresh BM mononuclear cells underwent single-cell 5’ RNA sequencing (precursor disease, n=16; NDMM, n=6; orthopaedic controls, n=3). Parallel 14-marker flow cytometry analysed PB and BM from precursor (PB=158, BM=18), NDMM (PB=37, BM=18), and HD (PB=9). Subsets included: transitional (CD24+CD38+), naïve (nBC; IgD+CD27-), switched memory (sMBC; IgD-CD27+), unswitched memory (usMBC; IgD+CD27+), and atypical (IgD-CD27-CD21-) B cells. Intracellular IL-10 was assessed post-CpG 7909 stimulation of SMM samples (BM n=6, PB n=3).
Results:
Integration with public datasets generated a single-cell atlas of 171 samples from 11 studies (HD n=86; MGUS n=15; SMM n=36; NDMM n=34). Six B-cell clusters were identified, comprising nBC, memory(mBC), precursor, atypical, activated and proliferating populations. Compared with precursor disease, NDMM contained fewer nBCs (44.1% versus 25.6%; p=0.05) and more mBCs (27.2% versus 35.9%; p=0.07); other clusters did not vary by stage.
To extend these findings, we performed flow cytometry in a large, uniformly processed, clinically annotated cohort. Mature B-cell subset composition did not differ between paired PB and BM samples (n=26), whereas precursor B-cells were enriched in BM. PB was therefore used for the larger cohort analysis. nBC frequency declined from HD to precursor disease to NDMM (61.4%, 48.4% and 36.7%; p=0.003), whereas sMBC frequency increased (13.9%, 17.9% and 25.8%; p=0.047). usMBCs showed a similar numerical trend (4.5%, 4.7% and 7.9%; p=0.07). The association between lower nBC frequency and more advanced disease remained significant after adjustment for age and tumour burden.
In precursor disease, sMBC frequency correlated with SMM 20/2/20 risk group (Spearman ρ=0.19, p=0.03) but not tumour burden. Immunoparesis associated with lower nBC frequency (ρ=-0.22, p=0.0056) and increased sMBC frequency (ρ=0.286, p=0.0031). Uninvolved IgG levels positively correlated with nBC frequency (ρ=0.52, p=0.0001). Total B-cell abundance fell with increasing age (ρ=-0.15, p=0.047), immune paresis (ρ=-0.251, p=0.0042), lower uninvolved IgG (ρ=0.39, p=0.005) and IgM levels (ρ=0.36, p<0.001), but not disease stage.
Following CpG stimulation, IL-10+ cells were detected in all subsets, and more frequently in BM than in paired PB (median in all B-cells 51.7% BM , 34.0% PB). In both tissues IL-10+ cells were more frequent among sMBCs and usMBCs than among nBCs and transitional B-cells (BM: 63.5% and 56.0% vs 30.2% and 36.4%; Friedman test with Dunn’s multiple comparisons p=0.016), although intracellular IL-10 abundance per positive cell did not differ. IL-10 production coincided with CD69 upregulation, a conventional activation marker (ρ=0.62, p=0.036); neither correlated with tumour infiltration.
Conclusions:
The B-cell compartment undergoes progressive remodelling across myeloma precursor disease and NDMM, characterised by nBC loss and mBC expansion. nBC loss is associated with disease stage independently of age and tumour burden and is linked to immunoparesis and reduced uninvolved IgG. In SMM, memory subsets are enriched for cells capable of producing IL-10 after stimulation, suggesting increased immunoregulatory potential. These findings identify B-cell remodelling as a feature of myeloma evolution that may contribute to impaired humoral immunity and merits investigation as a biomarker and potential mediator of progression.
DISCLOSURES
Louise Ainley, MD: No relevant conflicts of interest to declare.